What is the CVR number of Sygehusgrunden Komplementar ApS?

Sygehusgrunden Komplementar ApS is registered with CVR / Virk under CVR 43471449.

What is the revenue of Sygehusgrunden Komplementar ApS?

Sygehusgrunden Komplementar ApS reported revenue of DKK -13K in 2025.

Rasmus Færch chairs the board of Sygehusgrunden Komplementar ApS, in role since 2024.

Sygehusgrunden Komplementar ApS's registered address is Aksel Nørgaards Plads 7.

APSActive

CVR 43471449Aksel Nørgaards Plads 7, 7500 HolstebroActivities of holding companies· NACE 6421Est. 2022 · 3 years old— employees

Actively employed in the business

Name	Role	Member since
Current (1)
FS Finn Skov Management	Management	2026
Former (1)
TK Thomas Kristensen Leerberg Management	Management	2022 – 2026

Non-executive oversight

Name	Role	Member since
Current (8)
JN Jens Nyhus Deputy Chairman	Deputy Chairman	2026
KF Klaus Frank Flæng Board of Directors	Board of Directors	2026
MN Martin Nygaard Christoffersen Board of Directors	Board of Directors	2025
KT Kenneth Tønning Deputy Chairman	Deputy Chairman	2026
LA Lars Autrup Board of Directors	Board of Directors	2026
RF Rasmus Færch Chairman	Chairman	2024
ET Evy Tångberg Christensen Board of Directors	Board of Directors	2025
LM Lars Møller Board of Directors	Board of Directors	2025
Former (7)
AN Aksel Nørgaard Board of Directors	Board of Directors	2022 – 2024
CF Claus Fynbo Larsen Board of Directors	Board of Directors	2025 – 2025
BP Bente Priess Andersen Chairman	Chairman	2022 – 2022
NH Niels Højberg Chairman	Chairman	2023 – 2024
AC Anne Charlotte Mark Board of Directors	Board of Directors	2022 – 2025
CO Claus Omann Jensen Deputy Chairman	Deputy Chairman	2023 – 2024
HC Hans Christen Østerby Deputy Chairman	Deputy Chairman	2022 – 2026

As of last annual report

Shareholder	Type	Ownership	Votes	Since
FÆRCHFONDEN	Company	33.33–49.99%	33.33–49.99%	2022
Holstebro Kommune	Company	33.33–49.99%	33.33–49.99%	2022
Akselerator A/S	Company	10–14.99%	10–14.99%	2022

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.